PARP Inhibitor Market By Drug (Lynparza, Niraparib, Rucaparib and Others), By Indication (Ovarian cancer, Breast cancer, Prostate cancer, Lung cancer and Others), By Distribution Channel (Hospital pharmacies, Online pharmacies and Others), and By Region - Trends, Analysis and Forecast till 2034

According to the National Cancer Institute, Africa, Asia, Central America, and South America account for more than 60% of all new cancer cases worldwide, and these regions also account for 70% of all cancer-related deaths. The International Agency for Research on Cancer (IARC) estimates that, without accounting for factors like smoking, poor diet, physical inactivity, and fewer childbirths in economically developing countries that support the PARP inhibitor market, the global burden of cancer is expected to rise to 21.7 million new cases and 13 million cancer deaths by 2030 due to population growth and aging.